Member of the Association of American Physicians
His primary scientific interests are in Chronic lymphocytic leukemia, Leukemia, Cancer research, Immunology and Molecular biology. Chronic lymphocytic leukemia is a subfield of Internal medicine that he explores. Thomas J. Kipps has included themes like Gastroenterology and Oncology in his Internal medicine study.
The study incorporates disciplines such as Gene rearrangement, Gene expression profiling, Lymphocyte, Pharmacology and CD20 in addition to Leukemia. His work deals with themes such as Cell culture, breakpoint cluster region, Signal transduction and Chemokine receptor, which intersect with Cancer research. In Molecular biology, Thomas J. Kipps works on issues like B cell, which are connected to Cell biology and Synovial membrane.
Thomas J. Kipps focuses on Chronic lymphocytic leukemia, Immunology, Internal medicine, Cancer research and Leukemia. His Chronic lymphocytic leukemia study combines topics from a wide range of disciplines, such as Molecular biology and Antibody, B cell. His Immunology study combines topics in areas such as CD154 and CD38.
The various areas that Thomas J. Kipps examines in his Internal medicine study include Gastroenterology and Oncology. His Cancer research study incorporates themes from Cirmtuzumab, Apoptosis, Cancer and CD40. His Leukemia research incorporates elements of Cytotoxic T cell, CD5, Hematology and microRNA.
Chronic lymphocytic leukemia, Internal medicine, Cancer research, Ibrutinib and Oncology are his primary areas of study. His Chronic lymphocytic leukemia study results in a more complete grasp of Leukemia. His research in Leukemia intersects with topics in Hematology and Monoclonal.
His work on Venetoclax, Rituximab, Obinutuzumab and Progression-free survival as part of general Internal medicine study is frequently connected to In patient, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them. His Cancer research research incorporates themes from Cirmtuzumab, Cancer, Cell and Stem cell. His studies deal with areas such as Relapsed refractory, Chemoimmunotherapy, Ofatumumab and First line treatment as well as Oncology.
His main research concerns Chronic lymphocytic leukemia, Internal medicine, Ibrutinib, Leukemia and Cancer research. As part of one scientific family, Thomas J. Kipps deals mainly with the area of Chronic lymphocytic leukemia, narrowing it down to issues related to the Refractory, and often Tolerability. His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology and Oncology.
His study in Ibrutinib is interdisciplinary in nature, drawing from both Adverse effect, Fludarabine and [email protected] His studies in Leukemia integrate themes in fields like Monoclonal, Hematology, Disease, CD19 and Regulation of gene expression. His biological study spans a wide range of topics, including Cell, Cell growth, RNA splicing, Cirmtuzumab and Bruton's tyrosine kinase.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia
George Adrian Calin;Calin Dan Dumitru;Masayoshi Shimizu;Roberta Bichi.
Proceedings of the National Academy of Sciences of the United States of America (2002)
miR-15 and miR-16 induce apoptosis by targeting BCL2.
Amelia Cimmino;George Adrian Calin;Muller Fabbri;Marilena V. Iorio.
Proceedings of the National Academy of Sciences of the United States of America (2005)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
Michael Hallek;Bruce D. Cheson;Daniel Catovsky;Federico Caligaris-Cappio.
A MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic Leukemia
George Adrian Calin;Manuela Ferracin;Manuela Ferracin;Amelia Cimmino;Gianpiero Di Leva.
The New England Journal of Medicine (2005)
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
Richard R. Furman;Jeff P. Sharman;Steven E. Coutre;Bruce D. Cheson.
The New England Journal of Medicine (2014)
MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias
George Adrian Calin;Chang Gong Liu;Cinzia Sevignani;Manuela Ferracin.
Proceedings of the National Academy of Sciences of the United States of America (2004)
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
J. C. Byrd;J. R. Brown;Susan O'Brien;J. C. Barrientos.
The New England Journal of Medicine (2014)
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts;Matthew S. Davids;John M. Pagel;Brad S. Kahl.
The New England Journal of Medicine (2016)
CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment.
Jan A. Burger;Thomas J. Kipps;Thomas J. Kipps.
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.
Andreas Rosenwald;Ash A. Alizadeh;George Widhopf;Richard Simon.
Journal of Experimental Medicine (2001)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: